The AL amyloidosis treatment market attained a value of USD 4 billion in 2023. The market is likely to grow further at a CAGR of 9.08% during the forecast period of 2024-2032. Within this growth rate, the market value is estimated to reach about USD 8.70 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
AL amyloidosis or amyloid chain amyloidosis refers to a type of rare disorder amyloidosis. In this disorder, the accumulation of light chain proteins occurs in major organs, such as the heart and kidneys, among other body organs. This type of amyloidosis is also referred to as primary amyloidosis.
AL amyloidosis has a wide range of symptoms as it affects several organs of the body. The symptoms affecting the head and neck include light-headedness, a larger size of tongue, and rashes around the eyes. The clinical manifestations of arms and legs include swelling, burning, numbness, and tingling sensations. The cardiac-associated symptoms are chest pain, shortness of breath, and heart palpitations. Additionally, there are some intestinal and kidney-related problems such as constipation, diarrhoea, bloating, and poor appetite.
Several tests are performed to diagnose AL amyloidosis depending on the organs or systems affected by the disease. Different types of biopsies such as bone marrow biopsy, kidney biopsy, heart biopsy, and fat pad biopsy are commonly used sampling procedures to diagnose AL amyloidosis. Additional tests, such as an echocardiogram, electrocardiogram, cardiac MRI, and other urine and blood tests are used to confirm the presence of AL amyloidosis.
There are multiple treatment strategies for managing AL amyloidosis disease depending on the affected organ and severity of the disease. The commonly used therapeutic interventions are steroids, chemotherapy, immunotherapy, and bone marrow or stem cell transplants.
According to the global AL amyloidosis treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Treatment Type
Market Breakup by Diagnosis Type
AL Amyloidosis Treatment Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is primarily driven by the increasing prevalence of light-chain amyloidosis. The increased patient pool has led to the growing demand for diagnostics and therapeutics, thus attributing significantly to the market growth. AL amyloidosis affects 5 to 12 in 1000000 people globally. The disease is more prevalent in women as compared to men.
The rising geriatric population in developed and developing nations is also contributing to the increased market growth as this disease is more prevalent in people aged 60 and above.
Further, the AL amyloidosis treatment market is accelerated by the growing research and developmental activities, greater investments by public and private firms. The advancements in healthcare technologies and raising awareness about rare diseases are likely to bolster the market growth during the upcoming years.
The increasing number of collaborations and mergers or acquisitions among the strategic key players are aiding the market growth. For example, AstraZeneca, a key market player acquired Caelum Biosciences in 2021, which is expected to stimulate market expansion. The presence of a robust pipeline of novel targeted therapies for AL amyloidosis is also expected to provide lucrative opportunities for market growth.
North America is anticipated to hold a significant share of the AL amyloidosis treatment market owing to the advanced healthcare facilities, increased healthcare expenditure, and presence of significant key players. The Asia Pacific region is projected to be the fastest growing market due to the improving healthcare systems, rising awareness, and growing geriatric population.
The treatment for AL amyloidosis is highly personalised and individualised depending on the patient’s age, organ dysfunction, and severity of the disease. The treatment regimen is directed based on cardiac and hematologic biomarkers. The therapeutic interventions are based on the symptomatic treatment of the affected organs and systems.
The main aim of the AL amyloidosis treatment is to minimise the plasma cell clone to restore organ functionality. This is achieved by increasing the reabsorption of amyloid and henceforth, improving cardiac productivity rate and patient’s quality of living standards.
The medications used in the management of AL amyloidosis are anti-cancerous drugs or chemotherapy that stop the growth of abnormal cells that form amyloid. Certain types of blood thinners or anticlotting medications, such as Aspirin, are also prescribed to reduce the risk of blood clotting. The targeted therapies, such as Inotersen and Patisiran, interfere with the amyloid-forming faulty genes.
Apart from the medications, certain surgical and transplantation procedures have also been used for the treatment of AL amyloidosis. An autologous blood stem cell transplant is a procedure that involves the retransferring of the body’s stem cells back into the body. Organ transplant is another procedure used to replace organs that are severely damaged by amyloid deposits.
With the high treatment potential, the AL amyloidosis treatment market possesses an excellent opportunity for healthcare industries and pharmaceutical companies in extensive therapeutic methods.
With extensive research and development, new therapeutic interventions are being discovered. There is a need for full-fledged clinical trials before their availability for patient use.
Caelum and Alexion Biosciences, a key market player, is conducting the CARES clinical trials for evaluating the novel targeted therapy in combination with the standard therapy for the management of AL amyloidosis. This therapy has shown promising effects in the elimination of amyloid deposits in patients suffering from AL amyloidosis.
Ixazomib, a proteasome inhibitor, is a new drug tested under the Phase III stage of clinical trials. The drug has shown plausible therapeutic effects in the early phases of the clinical trials and hence, is anticipated to be the potential drug for the treatment of AL amyloidosis.
GlaxoSmithKline has initiated Phase II trials for a new drug, Belantamab Mafodotin, for the management of AL amyloidosis. This drug targets the Fc region of the monoclonal antibodies, to remove the fucose sugar units. This is anticipated to enhance the cell-mediated toxicity.
STI-6129, a new targeted therapy, is under investigation by Sorrento Therapeutics. The drug has demonstrated therapeutic efficacy in animal models and is expected to soon be used as a first-line treatment for treating AL amyloidosis.
These novel targeted therapies seem to grab the attention of key companies and investors, which will directly influence the development of this sector. This will help enable patient access and the growth of the market.
The report gives an in-depth analysis of the key players involved in the AL amyloidosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Treatment Type||
|Breakup by Diagnosis Type||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 AL Amyloidosis Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global AL Amyloidosis Treatment Market
8.1 Global AL Amyloidosis Treatment Market Overview
8.2 Global AL Amyloidosis Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global AL Amyloidosis Treatment Market Historical Value (2017-2023)
188.8.131.52 Global AL Amyloidosis Treatment Market Forecast Value (2024-2032)
8.2.2 Global AL Amyloidosis Treatment Market by Treatment Type
184.108.40.206 Market Overview
220.127.116.11.2 Proteasome Inhibitors
18.104.22.168.3 Cytotoxic Chemotherapy
22.214.171.124.4 Immunomodulatory Drugs
126.96.36.199.5 Autologous Hematopoietic Stem Cell Transplantation
188.8.131.52.6 Risk-adapted Melphalan
8.2.3 Global AL Amyloidosis Treatment Market by Diagnosis Type
184.108.40.206 Market Overview
220.127.116.11.1 Blood Tests
18.104.22.168.2 Magnetic Resonance Imaging (MRI)
8.2.4 Global AL Amyloidosis Treatment Market by Route of Administration
22.214.171.124 Market Overview
8.2.5 Global AL Amyloidosis Treatment Market by Distribution Channel
126.96.36.199 Market Overview
188.8.131.52.1 Hospital Pharmacies
184.108.40.206.2 Online Pharmacies
220.127.116.11.3 Retail Pharmacies
8.2.6 Global AL Amyloidosis Treatment Market by Region
18.104.22.168 Market Overview
22.214.171.124.1 North America
126.96.36.199.3 Asia Pacific
188.8.131.52.4 Middle East and Africa
184.108.40.206.5 Latin America
9 North America AL Amyloidosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe AL Amyloidosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
11 Asia Pacific AL Amyloidosis Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
12 Latin America AL Amyloidosis Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
13 Middle East and Africa AL Amyloidosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
14 Global AL Amyloidosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Janssen Global Services, LLC
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Caelum Biosciences (AstraZeneca)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Oncopeptides, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Bristol-Myers Squibb Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Acrotech Biopharma, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Prothena Corporation plc
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Alexion Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Takeda Pharmaceutical Company Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 GSK plc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Sorrento Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
16 AL Amyloidosis Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customizable as per client requirements.
The market size reached a value of USD 4 billion in 2023, driven by the rising prevalence of the condition.
The market is estimated to grow at a rate of 9.08% during the forecast period of 2024-2032 to attain a value of 8.70 billion by 2032.
The market growth is primarily driven by the rising cases of AL amyloidosis, the rising geriatric population, increasing research and development activities, and a robust pipeline of therapeutic products.
Based on the treatment type, the market is categorised into corticosteroids, proteasome inhibitors, cytotoxic chemotherapy, immunomodulatory drugs, autologous hematopoietic stem cell transplantation, risk-adapted melphalan, among others.
Based on the diagnosis, the market is segmented into blood tests, magnetic resonance imaging (MRI), ultrasound, and biopsy, among others.
Based on the route of administration, the market is bifurcated into oral and injectables, among others.
Based on the distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.
The key companies involved in the market are Janssen Global Services, LLC, Caelum Biosciences (AstraZeneca), Oncopeptides, Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, Inc., Sanofi, Prothena Corporation plc, Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GSK plc, and Sorrento Therapeutics, Inc., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.